Market Overview:
The global chemotherapy-induced neutropenia treatment market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising awareness about chemotherapy-induced neutropenia (CIN) and its treatments, and technological advancements in the field of CIN treatment. The global chemotherapy-induced neutropenia treatment market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into antibiotic therapy, colony-stimulating factor therapy (CSF), granulocyte transfusion (GT), splenectomy procedure, and others. Antibiotic therapy dominates this market owing to its high usage for treating CIN caused by various types of bacteria infections such as pneumonia or sepsis. CSF therapies are expected to witness high growth during the forecast period due their ability to improve patient outcomes by reducing infection rates and hospital stays. On the basis of application, hospitals account for a majority share in this market followed by ambulatory surgical centers (ASCs) and diagnostic centers.
Product Definition:
Chemotherapy-induced neutropenia treatment is the use of medications, such as Neupogen (filgrastim) and Granix (tbo-filgrastim), to increase the number of white blood cells in people receiving chemotherapy. Chemotherapy-induced neutropenia treatment is important because it can help reduce the risk of infection during chemotherapy.
Antibiotic Therapy:
Antibiotic therapy, usage and growth factor in chemotherapy-induced neutropenia treatment market.
The global antibiotic therapy, usage and growth factor in chemotherapy-induced neutropenia treatment market size was valued at USD 1.8 billion in 2018.
Colony-Stimulating Factor Therapy:
Colony-stimulating factor (CSF) is a protein that helps the bone marrow to produce new blood cells. It also aids in the recovery of patients from chemotherapy and radiation therapy. The treatment consists of infusion of recombinant human colony-stimulating factor into the vein along with frequent blood cell transfusions.
The process has an advantage over traditional treatments such as stem cell transplants, which are often complicated.
Application Insights:
The hospitals segment dominated the global chemotherapy-induced neutropenia treatment market in 2017. This is owing to factors such as availability of advanced healthcare facilities and skilled medical personnel, coupled with rising patient admissions due to cancer. Furthermore, increasing government funding for cancer care along with growing awareness about early diagnosis will further propel growth over the forecast period.
Ambulatory surgical centers (ASCs) are anticipated to witness lucrative growth over the forecast period owing to increasing incidence of blood disorders and an increase in number of procedures requiring blood transfusion therapy. In addition, favorable reimbursement policies for these centers will also boost revenue generation capacity over the coming years. However, ASCs face several challenges including high cost associated with them and a lack of uniformity in terms of standards followed by these centers across various regions which may hinder market growth during the study period.
Regional Analysis:
North America dominated the global chemotherapy-induced neutropenia treatment market in 2017. This is due to the presence of well-established healthcare facilities, availability of advanced medicines, and high patient awareness levels coupled with relatively higher healthcare expenditure in this region as compared to other regions. In addition, increasing initiatives by various non-profit organizations and government bodies for raising awareness regarding CIN treatment are also responsible for its large share. For instance, from 2014 to 2016, neutropenia related hospital admissions were reduced by 40% in children aged 1 - 17 years old as a result of chemo education program organized by Children's Hospital Colorado (U.S.).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the chemotherapy-induced neutropenia treatment market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in 2017 in the U.S., and this number is expected to rise in the coming years. This will lead to an increase in demand for chemotherapy-induced neutropenia treatments.
- Rising awareness about chemotherapy-induced neutropenia: There is a growing awareness among people about chemotherapy-induced neutropenia and its associated risks. This has led to an increase in demand for therapies that can prevent or treat this condition.
- Technological advancements: The development of novel therapies and drugs for treating chemotherapy-induced neutropenia has been a key factor driving growth of this market over the past few years. Some of these newer therapies include filgrastim (Neupogen) and pegfilgrastim (Neulasta), which are administered as subcutaneous injections and help reduce duration and severity of fever episodes caused by chemotherapeutic agents used to treat various types of cancers including leukemia, lymphoma, breast cancer, ovarian cancer etcetera . These advancements are likely to spur growth prospects for this market over the forecast period .
Scope Of The Report
Report Attributes
Report Details
Report Title
Chemotherapy-Induced Neutropenia Treatment Market Research Report
By Type
Antibiotic Therapy, Colony-Stimulating Factor Therapy, Granulocyte Transfusion, Splenectomy Procedure, Others
By Application
Hospitals, Ambulatory Surgical Center, Diagnostic Centers
By Companies
Amgen, Sanofi, Novartis AG, Baxter International, Teva Pharmaceuticals Industries, Apotex, Dr. Reddy’s Laboratory, Biogenomics Limited, Ligand Pharmaceuticals, Amgen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
135
Number of Tables & Figures
95
Customization Available
Yes, the report can be customized as per your need.
Global Chemotherapy-Induced Neutropenia Treatment Market Report Segments:
The global Chemotherapy-Induced Neutropenia Treatment market is segmented on the basis of:
Types
Antibiotic Therapy, Colony-Stimulating Factor Therapy, Granulocyte Transfusion, Splenectomy Procedure, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Ambulatory Surgical Center, Diagnostic Centers
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen
- Sanofi
- Novartis AG
- Baxter International
- Teva Pharmaceuticals Industries
- Apotex
- Dr. Reddy’s Laboratory
- Biogenomics Limited
- Ligand Pharmaceuticals
- Amgen
Highlights of The Chemotherapy-Induced Neutropenia Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antibiotic Therapy
- Colony-Stimulating Factor Therapy
- Granulocyte Transfusion
- Splenectomy Procedure
- Others
- By Application:
- Hospitals
- Ambulatory Surgical Center
- Diagnostic Centers
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Chemotherapy-Induced Neutropenia Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Chemotherapy-induced neutropenia (CIN) is a condition that occurs when the body's white blood cells are damaged by the chemotherapy treatment. CIN can lead to infections, which can be serious and even life-threatening. Treatment for CIN typically includes antibiotics to prevent infection and other treatments, such as IV fluids and blood transfusions, to help reduce the risk of death.
Some of the major players in the chemotherapy-induced neutropenia treatment market are Amgen, Sanofi, Novartis AG, Baxter International, Teva Pharmaceuticals Industries, Apotex, Dr. Reddy¢â‚¬â„¢s Laboratory, Biogenomics Limited, Ligand Pharmaceuticals, Amgen.
The chemotherapy-induced neutropenia treatment market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Chemotherapy-Induced Neutropenia Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Chemotherapy-Induced Neutropenia Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Chemotherapy-Induced Neutropenia Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Chemotherapy-Induced Neutropenia Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Chemotherapy-Induced Neutropenia Treatment Market Size & Forecast, 2018-2028
4.5.1 Chemotherapy-Induced Neutropenia Treatment Market Size and Y-o-Y Growth
4.5.2 Chemotherapy-Induced Neutropenia Treatment Market Absolute $ Opportunity
Chapter 5 Global Chemotherapy-Induced Neutropenia Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Chemotherapy-Induced Neutropenia Treatment Market Size Forecast by Type
5.2.1 Antibiotic Therapy
5.2.2 Colony-Stimulating Factor Therapy
5.2.3 Granulocyte Transfusion
5.2.4 Splenectomy Procedure
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Chemotherapy-Induced Neutropenia Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Chemotherapy-Induced Neutropenia Treatment Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Ambulatory Surgical Center
6.2.3 Diagnostic Centers
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Chemotherapy-Induced Neutropenia Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Chemotherapy-Induced Neutropenia Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Chemotherapy-Induced Neutropenia Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Chemotherapy-Induced Neutropenia Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Chemotherapy-Induced Neutropenia Treatment Market Size Forecast by Type
9.6.1 Antibiotic Therapy
9.6.2 Colony-Stimulating Factor Therapy
9.6.3 Granulocyte Transfusion
9.6.4 Splenectomy Procedure
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Chemotherapy-Induced Neutropenia Treatment Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Ambulatory Surgical Center
9.10.3 Diagnostic Centers
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Chemotherapy-Induced Neutropenia Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Chemotherapy-Induced Neutropenia Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Chemotherapy-Induced Neutropenia Treatment Market Size Forecast by Type
10.6.1 Antibiotic Therapy
10.6.2 Colony-Stimulating Factor Therapy
10.6.3 Granulocyte Transfusion
10.6.4 Splenectomy Procedure
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Chemotherapy-Induced Neutropenia Treatment Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Ambulatory Surgical Center
10.10.3 Diagnostic Centers
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Chemotherapy-Induced Neutropenia Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Chemotherapy-Induced Neutropenia Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Chemotherapy-Induced Neutropenia Treatment Market Size Forecast by Type
11.6.1 Antibiotic Therapy
11.6.2 Colony-Stimulating Factor Therapy
11.6.3 Granulocyte Transfusion
11.6.4 Splenectomy Procedure
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Chemotherapy-Induced Neutropenia Treatment Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Ambulatory Surgical Center
11.10.3 Diagnostic Centers
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Chemotherapy-Induced Neutropenia Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Chemotherapy-Induced Neutropenia Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Chemotherapy-Induced Neutropenia Treatment Market Size Forecast by Type
12.6.1 Antibiotic Therapy
12.6.2 Colony-Stimulating Factor Therapy
12.6.3 Granulocyte Transfusion
12.6.4 Splenectomy Procedure
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Chemotherapy-Induced Neutropenia Treatment Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Ambulatory Surgical Center
12.10.3 Diagnostic Centers
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Chemotherapy-Induced Neutropenia Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Chemotherapy-Induced Neutropenia Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Chemotherapy-Induced Neutropenia Treatment Market Size Forecast by Type
13.6.1 Antibiotic Therapy
13.6.2 Colony-Stimulating Factor Therapy
13.6.3 Granulocyte Transfusion
13.6.4 Splenectomy Procedure
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Chemotherapy-Induced Neutropenia Treatment Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Ambulatory Surgical Center
13.10.3 Diagnostic Centers
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Chemotherapy-Induced Neutropenia Treatment Market: Competitive Dashboard
14.2 Global Chemotherapy-Induced Neutropenia Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Amgen
14.3.2 Sanofi
14.3.3 Novartis AG
14.3.4 Baxter International
14.3.5 Teva Pharmaceuticals Industries
14.3.6 Apotex
14.3.7 Dr. Reddy’s Laboratory
14.3.8 Biogenomics Limited
14.3.9 Ligand Pharmaceuticals
14.3.10 Amgen
